Patient Centered Results for Uterine Fibroids
Launched by DUKE UNIVERSITY · Oct 6, 2014
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
COMPARE UF will enroll approximately 10,000 subjects across 9 clinical enrolling centers in the US. We anticipate recruitment to last approximately 24 months. Sites will consent interested patients and have them complete a patient contact information form to be used to contact the patient for telephone interviews. Following informed consent, the site will collect clinical information and several patient-reported outcomes scales, including the Uterine Fibroid Symptom Quality of Life Questionnaire (UFS-QOL), the Menopausal Rating Scale, and the EQ-5D, a standardized measure of general health ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of UF by imaging or pathology report within 2 years of enrollment initiation.
- • Menstrual period within 12 months
- Exclusion Criteria:
- • Post-menopausal
- • Men
- • 55 years old or older
About Duke University
Duke University, a leading academic and research institution located in Durham, North Carolina, is renowned for its commitment to advancing healthcare through innovative clinical research. With a strong emphasis on interdisciplinary collaboration, Duke conducts a wide array of clinical trials aimed at developing cutting-edge therapies and improving patient outcomes across various medical fields. The university's Clinical Research Institute provides comprehensive support for trial design, implementation, and regulatory compliance, ensuring that all research adheres to the highest ethical and scientific standards. Duke’s dedication to translating research findings into effective clinical practices underscores its role as a pivotal contributor to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
Boston, Massachusetts, United States
Jackson, Mississippi, United States
Detroit, Michigan, United States
Chapel Hill, North Carolina, United States
Ann Arbor, Michigan, United States
Boston, Massachusetts, United States
Bethesda, Maryland, United States
San Francisco, California, United States
Falls Church, Virginia, United States
Patients applied
Trial Officials
Evan R Myers, MD
Principal Investigator
Duke University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials